Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

BACKGROUND: Pancreatic cancer has a poor prognosis and few choices of therapy. For patients with adequate performance status, FOLFIRINOX or gemcitabine plus nab-paclitaxel are preferred first-line treatment. 5-Fluorouracil (5-FU)–based therapy (e.g. FOLFIRI, OFF, or FOLFOX) are often used in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Wainberg, Zev A., Feeney, Kynan, Lee, Myung Ah, Muñoz, Andrés, Gracián, Antonio Cubillo, Lonardi, Sara, Ryoo, Baek-Yeol, Hung, Annie, Lin, Yong, Bendell, Johanna, Hecht, J. Randolph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346629/
https://www.ncbi.nlm.nih.gov/pubmed/32641104
http://dx.doi.org/10.1186/s12885-020-07110-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346629/
https://www.ncbi.nlm.nih.gov/pubmed/32641104
http://dx.doi.org/10.1186/s12885-020-07110-x

Ejemplares similares